Production of biologically active scFv and VHH antibody fragments in Bifidobacterium longum

FEMS Microbiology Letters

Volumn 362, Issue 12, 2015, Pages

  Shkoporov, A N ^a,b   Khokhlova, E V ^a   Savochkin, K A ^b   Kafarskaia, L I ^a   Efimov, B A ^a  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b Pharmbacter LLC   (Russian Federation)

Author keywords

Antibody; Bifidobacterium; ScFv; Transformation; Vector; VHH

Indexed keywords

AMYB SIGNAL PEPTIDE; CLOSTRIDIUM DIFFICILE TOXIN A; I KAPPA B ALPHA; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; SIGNAL PEPTIDE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY A20.1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY A26.8; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY D2E7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADALIMUMAB; BACTERIUM ANTIBODY; ENDOTOXIN;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BIFIDOBACTERIUM LONGUM; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHOLOGICAL TRAIT; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BIFIDOBACTERIUM; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; DBA MOUSE; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; TRANSGENIC ORGANISM;

ADALIMUMAB; ANIMALS; ANTIBODIES, BACTERIAL; BIFIDOBACTERIUM; CELLS, CULTURED; ENDOTOXINS; GENE EXPRESSION; HUMANS; MALE; MICE, INBRED C57BL; MICE, INBRED DBA; ORGANISMS, GENETICALLY MODIFIED;

EID: 84940540674     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1093/femsle/fnv083     Document Type: Article

References (45)

1. Aguirre M, Collins MD. Lactic acid bacteria and human clinical infection. J Appl Bacteriol 1993;75:95-107.
2. Ahmad ZA, Yeap SK, Ali AM, et al. scFv antibody: principles and clinical application. Clin Dev Immunol 2012;2012: 980250.
3. AlFaleh K, Anabrees J. Efficacy and safety of probiotics in preterm infants. J Neonatal Perinatal Med 2013;6:1-9.
4. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol H 2006;4:754-9.
5. Brancaccio VF, Zhurina DS, Riedel CU. Tough nuts to crack: sitedirected mutagenesis of bifidobacteria remains a challenge. Bioengineered 2013;4:197-202.
6. Bolotin A, Wincker P, Mauger S, et al. The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL1403. Genome Res 2001;11:731-53.
7. Cronin M, Morrissey D, Rajendran S, et al. Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. Mol Ther 2010;18:1397-407.
8. de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biot 2008;111:1-66.
9. Deguchi Y, Morishita T, Mutai M. Comparative studies of water soluble vitamins among human species of bifidobacteria. Agr Biol Chem 1985;49:13-9.
10. Dimidi E, Christodoulides S, Fragkos KC, et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014;100:1075-84.
11. Dominguez W, O'Sullivan DJ. Developing an efficient and reproducible conjugation-based gene transfer system for bifidobacteria. Microbiology 2013;159:328-38.
12. Figueroa-Gonzalez I, Quijano G, Ramirez G, et al. Probiotics and prebiotics-perspectives and challenges. J Sci Food Agr 2011;91:1341-8.
13. Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect fromenteropathogenic infection through production of acetate. Nature 2011;469:543-7.
14. Ghouri YA, Richards DM, Rahimi EF, et al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014;7:473-87.
15. Guandalini S. Are probiotics or prebiotics useful in pediatric irritable bowel syndrome or inflammatory bowel disease? Front Med 2014;1:23.
16. Guglielmetti S, Mayo B, Alvarez-Martin P. Mobilome and genetic modification of bifidobacteria. Benef Microbes 2013;4: 143-66.
17. Guglielmi L, Martineau P. Expression of single-chain Fv fragments in E. coli cytoplasm. Methods Mol Biol 2009;562:215-24.
18. Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biot 2007;77:13-22.
19. Hussack G, Arbabi-Ghahroudi M, Mackenzie CR, et al. Isolation and characterization of Clostridium difficile toxin-specific single-domain antibodies. Methods Mol Biol 2012;911:211-39.
20. Kechagia M, Basoulis D, Konstantopoulou S, et al. Health benefits of probiotics: a review. ISRN Nutr 2013;2013:481651.
21. Keel MK, Songer JG. The distribution and density of Clostridium difficile toxin receptors on the intestinal mucosa of neonatal pigs. Vet Pathol 2007;44:814-22.
22. Khokhlova EV, Efimov BA, Kafarskaia LI, et al. Heterologous expression of secreted biologically active human interleukin- 10 in Bifidobacterium breve. Arch Microbiol 2010;192:769-74.
23. Khokhlova EV, Smeianov VV, Efimov BA, et al. Anti-inflammatory properties of intestinal Bifidobacterium strains isolated from healthy infants. Microbiol Immunol 2012;56:27-39.
24. Kim JE, Kim JY, Lee KW, et al. Cancer chemopreventive effects of lactic acid bacteria. J Microbiol Biotechnol 2007;17:1227-35.
25. Koenig JE, Spor A, Scalfone N, et al. Succession of microbial consortia in the developing infant gut microbiome. P Natl Acad Sci USA 2011;108:4578-85.
26. Kumar H, Salminen S, Verhagen H, et al. Novel probiotics and prebiotics: road to the market. Curr Opin Biotechnol 2015;32:99-103.
27. Limaye SA, Haddad RI, Cilli F, et al. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 2013;119:4268-76.
28. Losurdo L, Quintieri L, Caputo L, et al. Cloning and expression of synthetic genes encoding angiotensin-I converting enzyme (ACE)-inhibitory bioactive peptides in Bifidobacterium pseudocatenulatum. FEMS Microbiol Lett 2013;340:24-32.
29. Ma Y, Luo Y, Huang X, et al. Construction of Bifidobacterium infantis as a live oral vaccine that expresses antigens of the major fimbrial subunit (CfaB) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic Escherichia coli. Microbiology 2012;158:498-504.
30. Paton AW, Morona R, Paton JC. Designer probiotics for prevention of enteric infections. Nat Rev Microbiol 2006;4:193-200.
31. Paton AW, Morona R, Paton JC. Bioengineered bugs expressing oligosaccharide receptor mimics: toxin-binding probiotics for treatment and prevention of enteric infections. Bioeng Bugs 2010;1:172-7.
32. Pompei A, Cordisco L, Amaretti A, et al. Folate production by bifidobacteria as a potential probiotic property. Appl Environ Microb 2007;73:179-85.
33. Rajpal A, Beyaz N, Haber L, et al. A general method for greatly improving the affinity of antibodies by using combinatorial libraries. P Natl Acad Sci USA 2005;102:8466-71.
34. Rothman SW. Technique for measuring 50% end points in cytotoxicity assays for Clostridium difficile toxins. J Clin Pathol 1986;39:672-6.
35. Shkoporov AN, Efimov BA, Khokhlova EV, et al. Characterization of plasmids from human infant Bifidobacterium strains: sequence analysis and construction of E. coli-Bifidobacterium shuttle vectors. Plasmid 2008;60:136-48.
36. Shkoporov AN, Efimov BA, Khokhlova EV, et al. Draft genome sequences of two pairs of human intestinal Bifidobacterium longum subsp. longum strains, 44B and 1-6B and 35B and 2- 2B, consecutively isolated from two children after a 5-year time period. Genome Announc 2013;1:e00234-13.
37. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-5.
38. Turroni F, Bottacini F, Foroni E, et al. Genome analysis of Bifidobacterium bifidum PRL2010 reveals metabolic pathways for host-derived glycan foraging. P Natl Acad Sci USA 2010;107: 19514-9.
39. Turroni F, Peano C, Pass DA, et al. Diversity of bifidobacteria within the infant gut microbiota. PLoS One 2012;7: e36957.
40. Urben LM, Wiedmar J, Boettcher E, et al. Bugs or drugs: are probiotics safe for use in the critically ill? Curr Gastroenterol Rep 2014;16:388.
41. Vandenbroucke K, de Haard H, Beirnaert E, et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2010;3:49-56.
42. Villatoro-Hernandez J, Montes-de-Oca-Luna R, Kuipers OP. Targeting diseases with genetically engineered Lactococcus lactis and its course towards medical translation. Expert Opin Biol Th 2011;11:261-7.
43. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012;486:222-7.
44. Yin Y, Kou L, Wang JJ, et al. Therapeutic efficacy of Bifidobacterium longum-mediated human interleukin-2 with endostatin or TRAIL in transplanted tumors in mice. Exp Ther Med 2012;3:481-6.
45. Yu Z, Huang Z, Sao C, et al. Bifidobacterium as an oral delivery carrier of interleukin-12 for the treatment of Coxsackie virus B3-induced myocarditis in the Balb/c mice. Int Immunopharmacol 2012;12:125-30.